Although the use of epidrugs in cancer is still in its early stages, several anticancer therapeutic drugs targeting epigenetic modifiers, such as DNMT, EZH2 and HDAC, have been approved by the FDA and used in clinics; additional epigenetic drugs targeting chromatin modifiers are currently under clinical trial investigation (for review [27]). The gene discussed is EZH2; the disease is cancer.